Skip to main content
Erschienen in: Diabetology International 4/2012

01.12.2012 | Report of the committee

Report of the Committee of the Japan Diabetes Society on the Research of Fulminant and Acute-onset Type 1 Diabetes Mellitus: New Diagnostic Criteria of Fulminant Type 1 Diabetes Mellitus (2012)

verfasst von: Akihisa Imagawa, Toshiaki Hanafusa, Takuya Awata, Hiroshi Ikegami, Yasuko Uchigata, Haruhiko Osawa, Eiji Kawasaki, Yumiko Kawabata, Tetsuro Kobayashi, Akira Shimada, Ikki Shimizu, Kazuma Takahashi, Masao Nagata, Hideichi Makino, Taro Maruyama

Erschienen in: Diabetology International | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

We have revised a part of the diagnostic criteria for fulminant type 1 diabetes. The new criteria were set both to express the essence of this disease of rapid increase of patients’ blood glucose and to be highly sensitive to reduce the misdiagnosis. After analyzing the data of 382 patients with newly-diagnosed fulminant type 1 diabetes, we adopted the HbA1c level of 8.7 % (NGSP value). The new criterion indicates 100 % of sensitivity and best value by ROC (receiver operation curve) analysis. In addition, we added a comment that “This value (HbA1c < 8.7 % in NGSP) is not applicable for patients with previously diagnosed glucose intolerance” on the new criteria and also a comment that “Association with HLA DRB1*04:05-DQB1*04:01 is reported” as a related finding. We did not revise the screening criteria and the other part of the diagnostic criteria, because they are still reliable.
Literatur
1.
Zurück zum Zitat Imagawa A, Hanafusa T, Awata T, Ikegami H, Uchigata Y, Osawa H, Kawasaki E, Kawabata Y, Kobayashi T, Shimada A, Shimizu I, Takahashi K, Nagata M, Makino H, Maruyama T. Report of the Committee of Japan Diabetes Society on the Research of Fulminant and Acute-onset Type 1 Diabetes Mellitus: New Diagnostic Criteria of Fulminant Type 1 Diabetes Mellitus. J Japan Diab Soc. 2012;55:815–20 (Japanese). Imagawa A, Hanafusa T, Awata T, Ikegami H, Uchigata Y, Osawa H, Kawasaki E, Kawabata Y, Kobayashi T, Shimada A, Shimizu I, Takahashi K, Nagata M, Makino H, Maruyama T. Report of the Committee of Japan Diabetes Society on the Research of Fulminant and Acute-onset Type 1 Diabetes Mellitus: New Diagnostic Criteria of Fulminant Type 1 Diabetes Mellitus. J Japan Diab Soc. 2012;55:815–20 (Japanese).
2.
Zurück zum Zitat Imagawa A, Hanafusa T, Miyagawa J, Osaka IDDM Study Group. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. N Engl J Med. 2000;342:301–7.PubMedCrossRef Imagawa A, Hanafusa T, Miyagawa J, Osaka IDDM Study Group. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. N Engl J Med. 2000;342:301–7.PubMedCrossRef
3.
Zurück zum Zitat Imagawa A, Hanafusa T, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Toyoda T, Maruyama T, Makino H. Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care. 2003;26:2345–52.PubMedCrossRef Imagawa A, Hanafusa T, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Toyoda T, Maruyama T, Makino H. Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care. 2003;26:2345–52.PubMedCrossRef
4.
Zurück zum Zitat Hanafusa T, Imagawa A, Iwahashi H, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Maruyama T, Makino H. Report of Japan Diabetes Society Committee on fulminant type 1 diabetes mellitus research: epidemiological and clinical analysis and proposal of diagnostic criteria. J Japan Diab Soc. 2005;48(suppl1):A1–13. (Japanese). Hanafusa T, Imagawa A, Iwahashi H, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Maruyama T, Makino H. Report of Japan Diabetes Society Committee on fulminant type 1 diabetes mellitus research: epidemiological and clinical analysis and proposal of diagnostic criteria. J Japan Diab Soc. 2005;48(suppl1):A1–13. (Japanese).
5.
Zurück zum Zitat Imagawa A, Hanafusa T, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Maruyama T, Makino H. Different contribution of class II HLA in fulminant and typical autoimmune type 1 diabetes mellitus. Diabetologia. 2005;48:294–300. Erratum in: Diabetologia. 2008;51:524–6. Imagawa A, Hanafusa T, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Maruyama T, Makino H. Different contribution of class II HLA in fulminant and typical autoimmune type 1 diabetes mellitus. Diabetologia. 2005;48:294–300. Erratum in: Diabetologia. 2008;51:524–6.
6.
Zurück zum Zitat Shimizu I, Makino H, Hanafusa T, Imagawa A, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Maruyama T. Immunogenetic characteristics of fulminant type 1 diabetes mellitus associated with pregnancy: a nationwide survey. J Japan Diab Soc. 2005;48(suppl1):A15–9. (Japanese). Shimizu I, Makino H, Hanafusa T, Imagawa A, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Maruyama T. Immunogenetic characteristics of fulminant type 1 diabetes mellitus associated with pregnancy: a nationwide survey. J Japan Diab Soc. 2005;48(suppl1):A15–9. (Japanese).
7.
Zurück zum Zitat Shimizu I, Makino H, Imagawa A, Iwahashi H, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Maruyama T, Hanafusa T. Clinical and immunogenetic characteristics of fulminant type 1 diabetes associated with pregnancy. J Clin Endocrinol Metab. 2006;91:471–6.PubMedCrossRef Shimizu I, Makino H, Imagawa A, Iwahashi H, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Maruyama T, Hanafusa T. Clinical and immunogenetic characteristics of fulminant type 1 diabetes associated with pregnancy. J Clin Endocrinol Metab. 2006;91:471–6.PubMedCrossRef
8.
Zurück zum Zitat Shimizu I, Makino H, Imagawa A, Iwahashi H, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Maruyama T, Hanafusa T. Clinical and immunogenetic characteristics of fulminant type 1 diabetes associated with pregnancy: report of the Japan Diabetes Society Committee on Fulminant Type 1 Diabetes Mellitus Research. J Japan Diab Soc. 2006;49:755–60. (Japanese). Shimizu I, Makino H, Imagawa A, Iwahashi H, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Maruyama T, Hanafusa T. Clinical and immunogenetic characteristics of fulminant type 1 diabetes associated with pregnancy: report of the Japan Diabetes Society Committee on Fulminant Type 1 Diabetes Mellitus Research. J Japan Diab Soc. 2006;49:755–60. (Japanese).
9.
Zurück zum Zitat Kawasaki E, Shimizu I, Hanafusa T, Imagawa A, Iwahashi H, Uchigata Y, Kanatsuka A, Kobayashi T, Shimada A, Maruyama T, Makino H. Nationwide survey on the prevalence of type 1 diabetes associated with pregnancy. Diabetes Pregnancy. 2006;6:104–7. (Japanese). Kawasaki E, Shimizu I, Hanafusa T, Imagawa A, Iwahashi H, Uchigata Y, Kanatsuka A, Kobayashi T, Shimada A, Maruyama T, Makino H. Nationwide survey on the prevalence of type 1 diabetes associated with pregnancy. Diabetes Pregnancy. 2006;6:104–7. (Japanese).
10.
Zurück zum Zitat Hanafusa T, Imagawa A, Iwahashi H, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Maruyama T, Makino H, Murase Y, Ikegami H. Report of the committee of the Japan Diabetes Society on research on fulminant type 1 diabetes mellitus: analysis of HLA serotype and diabetic microangiopathy. J Japan Diab Soc. 2007;50:825–33. (Japanese). Hanafusa T, Imagawa A, Iwahashi H, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Maruyama T, Makino H, Murase Y, Ikegami H. Report of the committee of the Japan Diabetes Society on research on fulminant type 1 diabetes mellitus: analysis of HLA serotype and diabetic microangiopathy. J Japan Diab Soc. 2007;50:825–33. (Japanese).
11.
Zurück zum Zitat Hanafusa T, Imagawa A, Iwahashi H, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Maruyama T, Makino H. Report of the Japan Diabetes Society’s Committee on fulminant type 1 diabetes mellitus: analysis of antiviral antibodies at disease onset. J Japan Diab Soc. 2008;51:531–6. (Japanese). Hanafusa T, Imagawa A, Iwahashi H, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Maruyama T, Makino H. Report of the Japan Diabetes Society’s Committee on fulminant type 1 diabetes mellitus: analysis of antiviral antibodies at disease onset. J Japan Diab Soc. 2008;51:531–6. (Japanese).
12.
Zurück zum Zitat Imagawa A, Hanafusa T, Iwahashi H, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Maruyama T, Makino H. Uniformity in clinical and HLA-DR status regardless of age and gender within fulminant type 1 diabetes. Diabetes Res Clin Pract. 2008;82:233–7.PubMedCrossRef Imagawa A, Hanafusa T, Iwahashi H, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Maruyama T, Makino H. Uniformity in clinical and HLA-DR status regardless of age and gender within fulminant type 1 diabetes. Diabetes Res Clin Pract. 2008;82:233–7.PubMedCrossRef
13.
Zurück zum Zitat Takaike H, Uchigata Y, Iwamoto Y, Imagawa A, Iwahashi H, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Hanafusa T, Maruyama T, Makino H. Nationwide survey to compare the prevalence of transient elevation of liver transaminase during treatment of diabetic ketosis or ketoacidosis in new-onset acute and fulminant type 1 diabetes mellitus. Ann Med. 2008;40:395–400.PubMedCrossRef Takaike H, Uchigata Y, Iwamoto Y, Imagawa A, Iwahashi H, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Hanafusa T, Maruyama T, Makino H. Nationwide survey to compare the prevalence of transient elevation of liver transaminase during treatment of diabetic ketosis or ketoacidosis in new-onset acute and fulminant type 1 diabetes mellitus. Ann Med. 2008;40:395–400.PubMedCrossRef
14.
Zurück zum Zitat Kawabata Y, Ikegami H, Awata T, Imagawa A, Maruyama T, Kawasaki E, Tanaka S, Shimada A, Osawa H, Kobayashi T, Hanafusa T, Tokunaga K, The Committee on Type 1 Diabetes, Japan Diabetes Society. Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset. Diabetologia. 2009;52:2513–21.PubMedCrossRef Kawabata Y, Ikegami H, Awata T, Imagawa A, Maruyama T, Kawasaki E, Tanaka S, Shimada A, Osawa H, Kobayashi T, Hanafusa T, Tokunaga K, The Committee on Type 1 Diabetes, Japan Diabetes Society. Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset. Diabetologia. 2009;52:2513–21.PubMedCrossRef
15.
Zurück zum Zitat Koga M, Murai J, Saito H, Kasayama S, Imagawa A, Hanafusa T. Japan Diabetes Society’s Committee on Research on Type 1 Diabetes. Serum glycated albumin to haemoglobin A(1C) ratio can distinguish fulminant type 1 diabetes mellitus from type 2 diabetes mellitus. Ann Clin Biochem. 2010;47:313–7.PubMedCrossRef Koga M, Murai J, Saito H, Kasayama S, Imagawa A, Hanafusa T. Japan Diabetes Society’s Committee on Research on Type 1 Diabetes. Serum glycated albumin to haemoglobin A(1C) ratio can distinguish fulminant type 1 diabetes mellitus from type 2 diabetes mellitus. Ann Clin Biochem. 2010;47:313–7.PubMedCrossRef
16.
Zurück zum Zitat Nakamura K, Kawasaki E, Imagawa A, Awata T, Ikegami H, Uchigata Y, Kobayashi T, Shimada A, Nakanishi K, Makino H, Maruyama T, The Research Committee on Type 1 Diabetes of the Japan Diabetes Society. Type 1 diabetes and interferon therapy: a nationwide survey in Japan. Diabetes Care. 2011;34:2084–9.PubMedCrossRef Nakamura K, Kawasaki E, Imagawa A, Awata T, Ikegami H, Uchigata Y, Kobayashi T, Shimada A, Nakanishi K, Makino H, Maruyama T, The Research Committee on Type 1 Diabetes of the Japan Diabetes Society. Type 1 diabetes and interferon therapy: a nationwide survey in Japan. Diabetes Care. 2011;34:2084–9.PubMedCrossRef
17.
Zurück zum Zitat Tsutsumi C, Imagawa A, Ikegami H, Makino H, Kobayashi T, Hanafusa T, The Japan Diabetes Society Committee on Type 1 Diabetes Mellitus Research. Class II HLA genotype in fulminant type 1 diabetes –a nationwide survey with reference to glutamic acid decarboxylase antibodies. J Diabetes Invest. 2012;3:62–9.CrossRef Tsutsumi C, Imagawa A, Ikegami H, Makino H, Kobayashi T, Hanafusa T, The Japan Diabetes Society Committee on Type 1 Diabetes Mellitus Research. Class II HLA genotype in fulminant type 1 diabetes –a nationwide survey with reference to glutamic acid decarboxylase antibodies. J Diabetes Invest. 2012;3:62–9.CrossRef
18.
Zurück zum Zitat Committee on the Standardization of Diabetes Mellitus-Related Laboratory Testing of Japan Diabetes Society. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Diabetol Int. 2012;3:8–10.CrossRef Committee on the Standardization of Diabetes Mellitus-Related Laboratory Testing of Japan Diabetes Society. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Diabetol Int. 2012;3:8–10.CrossRef
19.
Zurück zum Zitat Committee on the Standardization of Diabetes Mellitus-Related Laboratory Testing of Japan Diabetes Society. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Invest. 2012;3:39–40.CrossRef Committee on the Standardization of Diabetes Mellitus-Related Laboratory Testing of Japan Diabetes Society. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Invest. 2012;3:39–40.CrossRef
20.
Zurück zum Zitat Hirata H, Shimada A, Imagawa A, Awata T, Ikegami H, Uchigata Y, Osawa H, Kawasaki E, Kawabata Y, Kobayashi T, Shimizu I, Takahashi K, Nagata M, Makino H, Maruyama T, Hanafusa T, Committee on Type 1 diabetes. Clinical characteristics of cases that progress rapidly from type 2 diabetes to insulin deficiency like fulminant type 1 diabetes: subcommittee report on fulminant and acute type 1 diabetes, Committee on type 1 diabetes, Japan Diabetes Society. J Japan Diab Soc. 2012;55:505–11. (Japanese). Hirata H, Shimada A, Imagawa A, Awata T, Ikegami H, Uchigata Y, Osawa H, Kawasaki E, Kawabata Y, Kobayashi T, Shimizu I, Takahashi K, Nagata M, Makino H, Maruyama T, Hanafusa T, Committee on Type 1 diabetes. Clinical characteristics of cases that progress rapidly from type 2 diabetes to insulin deficiency like fulminant type 1 diabetes: subcommittee report on fulminant and acute type 1 diabetes, Committee on type 1 diabetes, Japan Diabetes Society. J Japan Diab Soc. 2012;55:505–11. (Japanese).
Metadaten
Titel
Report of the Committee of the Japan Diabetes Society on the Research of Fulminant and Acute-onset Type 1 Diabetes Mellitus: New Diagnostic Criteria of Fulminant Type 1 Diabetes Mellitus (2012)
verfasst von
Akihisa Imagawa
Toshiaki Hanafusa
Takuya Awata
Hiroshi Ikegami
Yasuko Uchigata
Haruhiko Osawa
Eiji Kawasaki
Yumiko Kawabata
Tetsuro Kobayashi
Akira Shimada
Ikki Shimizu
Kazuma Takahashi
Masao Nagata
Hideichi Makino
Taro Maruyama
Publikationsdatum
01.12.2012
Verlag
Springer Japan
Erschienen in
Diabetology International / Ausgabe 4/2012
Print ISSN: 2190-1678
Elektronische ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-012-0098-3

Weitere Artikel der Ausgabe 4/2012

Diabetology International 4/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Eingreifen von Umstehenden rettet vor Erstickungstod!

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.